In the acquisition of the resistance to trastuzumab/lapatinib, there is a possibility that a switch to Yes1 was induced to breast cancer cells depending on HER2 for proliferation, as dasatinib alone had an enough power to treat the resistant cells. Here, ERBB2 is linked to breast carcinoma.